দেশ: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
PREGABALIN
RANBAXY PHARMACEUTICALS CANADA INC.
N02BF02
PREGABALIN
300MG
CAPSULE
PREGABALIN 300MG
ORAL
100
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0151121008; AHFS:
APPROVED
2013-11-07
_ _ _Pr_ _RAN_ _™_ _-PREGABALIN (Pregabalin Capsules) Product Monograph_ _ _ _Page 1 of 61_ PRODUCT MONOGRAPH Pr RAN ™ -PREGABALIN Pregabalin Capsules 25 mg, 50 mg, 75 mg, 150 mg, 225 mg, 300 mg ANALGESIC AGENT Ranbaxy Pharmaceuticals Canada Inc., 126 East Drive Brampton, ON L6T 1C1 Date of Revision: March 24, 2020 Submission Control No: 237057 RAN trademark owned by Sun Pharmaceutical Industries Ltd. _ _ _Pr_ _RAN_ _™_ _-PREGABALIN (Pregabalin Capsules) Product Monograph_ _ _ _Page 2 of 61_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION .....................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS .................................................................................................4 ADVERSE REACTIONS ..................................................................................................15 DRUG INTERACTIONS ................................................................................................33 DOSAGE AND ADMINISTRATION ...........................................................................35 OVERDOSAGE ...............................................................................................................37 ACTION AND CLINICAL PHARMACOLOGY ............................................................38 STORAGE AND STABILITY........................................................................................41 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................41 PART II: SCIENTIFIC INFORMATION ...............................................................................43 PHARMACEUTICAL INFORMATION ..........................................................................43 CLINICAL TRIALS ........................................................................................................44 D সম্পূর্ণ নথি পড়ুন